Sight Sciences Reports Strong Q4, Reduced Losses, and Positive 2026 Revenue Guidance
Summary
Sight Sciences, Inc. reported a return to revenue growth in Q4 2025, significantly reduced its net loss, and provided optimistic revenue guidance for 2026, driven by targeted investments in its Interventional Dry Eye segment.
Key Events
-
Q4 2025 Revenue Growth
Reported $20.4 million in Q4 2025 revenue, a 7% increase year-over-year, matching analyst estimates.
-
Significant Loss Reduction
Net loss for Q4 2025 decreased to $4.2 million ($0.08 per share) from $11.8 million ($0.23 per share) in the prior year.
-
Strong Cash Position
Ended 2025 with $92.0 million in cash and cash equivalents, with reduced cash usage to $0.4 million in Q4.
-
Positive 2026 Revenue Guidance
Projected full-year 2026 revenue between $82 million and $88 million, representing 6% to 14% growth compared to full year 2025.
Analysis
The company's Q4 2025 results demonstrate improved financial performance, with a 7% year-over-year revenue increase and a substantial reduction in net loss. This positive momentum is expected to continue into 2026, as evidenced by the projected 6% to 14% revenue growth. The strategic increase in operating expenses for 2026, focused on market access and commercial resources for Interventional Dry Eye, indicates a clear growth strategy. Investors should monitor the execution of these investments and the continued expansion of the Interventional Dry Eye segment.
At the time of this filing, SGHT was trading at $5.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $286M. The 52-week trading range was $2.03 to $9.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.